NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 NATURAL CAPSULES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q1FY27 Revenue: ₹48.71 Cr (down 17% Q-o-Q, up 8% Y-o-Y) • Q1FY27 EBITDA: ₹1.12 Cr (do | 2026-08-13 |
| Quarterly results · Q1 FY27 NATURAL CAPSULES LIMITED - Q1FY27 SUMMARY HEADLINE NUMBERS • Revenue: ₹48.71 Cr (down 17% Q-o-Q, down 8% Y-o-Y) • EBITDA: ₹1.12 Cr (down 16% Q-o-Q, | 2026-08-13 |
| Annual report FY2026 NATURAL CAPSULES LIMITED - FY2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations: ₹18,720.46 lakhs (FY26) vs ₹16,920.55 lak | 2026-07-17 |
| Q4 FY26 earnings call NATURAL CAPSULES LIMITED – Q4 FY26 EARNINGS CALL SUMMARY --- HEADLINE NUMBERS • Q4 FY26 Revenue: Rs. 58.45 crores (55% QoQ growth, 30% YoY growth) | 2026-06-03 |
| Investor presentation · Q4 FY26 NATURAL CAPSULES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q4FY26 Revenue: ₹58.45 Cr (55% Q-o-Q, 30% Y-o-Y growth) • Q4FY26 EBITDA: ₹1.33 Cr (15 | 2026-05-28 |
| Quarterly results · Q4 FY26 NATURAL CAPSULES LIMITED – COMPANY DOCUMENT SUMMARY HEADLINE NUMBERS • Paid-up Share Capital increased: From Rs. 10,38,61,540 to Rs. 10,41,11,540 fo | 2026-05-27 |
| Quarterly results · Q3 FY26 NATURAL CAPSULES LIMITED – COMPANY DOCUMENT SUMMARY HEADLINE NUMBERS • Share Capital Increase: Paid-up share capital increased from Rs. 10,34,11,540 | 2026-02-13 |
| Investor presentation NATURAL CAPSULES LIMITED – INVESTOR SUMMARY Investor Presentation, February 2026 --- HEADLINE NUMBERS • Q3FY26 Revenue: ₹37.75 Cr (down 18% Q-o-Q, | 2026-02-13 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Natural Capsules Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.